Medically, you don’t have to taper off semaglutide, but many experts recommend it when stopping the medication. Some ...

Higher semaglutide dose of 7.2 mg was associated with superior weight loss and comparable safety outcomes among patients with obesity.

A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy – without ...

Ozempic may improve blood sugar a few weeks after starting, with full results appearing after about eight weeks. For weight ...

Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill.

To explore the latest breakthroughs in proteomics, GEN spoke with five companies at the forefront of proteomic innovation.

Henry Meds is a subscription-based telehealth platform that focuses on treatment for endocrine-related conditions. Offerings ...

GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal "bias." ...

Costco is partnering with the healthcare company Novo Nordisk to give members access to GLP-1 medications at just $499 for a ...

A study presented at the European Congress of Cardiology links GLP-1 drugs with a reduction in hospitalizations and deaths ...

Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug ...

A woman's abdominal discomfort turned out to be caused by a build up of food in her stomach. And the treatment involved diet soda.